The era of generic weight loss drugs is approaching, and the first batch of patents for GLP drugs have expired, leading to a fierce competition among competitors
影殇·天问
发表于 2024-4-8 18:14:16
3802
0
0
The global weight loss drug market is currently divided into two parts. Novo Nordisk's Wegovy and Ozempic, as well as Eli Lilly's Zepbound and Mounjaro, are the most sought after and effective drugs in the market.
However, both companies are unable to provide drugs to more consumers due to production capacity issues. But this has also made the market for generic weight-loss drugs hot. The industry predicts that by 2030, the market size of GLP generic drugs will reach 100 billion US dollars.
The global patent for Saxenda, the injection of Liraglutide, the main component of Novo Nordisk's previous generation product, will expire in some countries this year. It is also one of the first GLP-1 drugs to lose patent protection. Last February, it had already lost patent protection in the Chinese market.
Compared to Wegovy and Ozempic, Saxenda is now somewhat like "tears of the times" (referring to outdated things), but its efficacy is not enough to make up for in quantity. The influx of generic drug companies will create a strong supply of generic drugs and lower prices, thereby expanding the market.
Among them, Biocon, a leading generic drug company in India, has obtained a license to replicate Saxenda in the UK. The CEO of the company, Siddharth Mittal, confidently stated that his team is ensuring Biocon's leading position in the generic pharmaceutical market. The company has also submitted applications to regulatory agencies in the United States and Europe to replicate the drug Liraglutide.
The future is bright
Weight loss pills have already created record breaking profits for Novo Nordisk and Lilly, which has caught the attention of other pharmaceutical companies, and generic drugs are the key way for them to openly compete for market share.
Biocon is a typical example of this. The company stated that it is building infrastructure to seize strategic opportunities centered around GLP drugs. Liraglutide products are just the beginning, waiting for the expiration of patents for more effective Smegglutide and Tezepamide products. The generic drug market is bound to ignite a greater wave of competition.
Mittal stated that weight loss drugs will be a very attractive market for the next 20 years, and the UK's approval of Biocon's production of generic Liraglutide demonstrates Biocon's ability to seize this opportunity.
There are also leaders in the Chinese market. Last year, the Liraglutide biosimilar developed by East China Pharmaceutical was approved for the treatment of obesity. Hangzhou Jiuyuan Genetic Engineering Co., Ltd. announced last week that it is applying to sell Megglutide generic drugs in China to control the blood sugar of patients with type 2 diabetes.
Jiuyuan Genetic Engineering also pointed out that it cannot commercialize drugs before the patent expires unless a court with jurisdiction determines that the patent is invalid. According to Novo Nordisk's annual report, the patent for its semaglutide drug in China will expire in 2026, while the patent for the European and American markets will expire from 2031 to 2032.
Jiuyuan Gene Factory also emphasized that the Chinese market potential of Smegglutide is enormous, with its scale increasing from 2.5 billion RMB in 2022 to 43.9 billion RMB in 2032, with a compound annual growth rate of up to 33%.
CandyLake.com 系信息发布平台,仅提供信息存储空间服务。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
声明:该文观点仅代表作者本人,本文不代表CandyLake.com立场,且不构成建议,请谨慎对待。
猜你喜欢
- Digital Intelligence Morning Attendance | Nvidia released the humanoid robot training platform, and ByteDance became the first batch of enterprises to join
- AstraZeneca's market value has surpassed £ 200 billion for the first time! The bold bet on anti-cancer drugs is yielding results
- The US government announces the results of the first batch of "drug procurement" negotiations. Gaza ceasefire talks are highly divided. Global market
- Bristol Myers Squibb's original tumor treatment drug Abraxane has been officially launched in China
- The first batch of Apple 16 ProMax is not available in seconds! The trend of idle fish transfer is rising, and sellers are raising prices by 400-1000 yuan
- OpenAI announces receipt of Nvidia's first batch of DGX B200 engineering machines
- He Xiaopeng: Xiaopeng P7+'s first batch of production vehicles officially rolled off the production line
- TSMC reportedly receives the first batch of high NA EUV lithography machines from ASML before the end of the year
- New Consumer Daily | Wenjie's new M7 has delivered over 170000 units cumulatively; Tesla and six other car companies were among the first to receive the national automobile privacy protection label
- Faraday Future says first batch of FX prototype cars will be shipped to FF's US headquarters
-
知名做空机构香橼研究(Citron Research)周四(11月21日)在社交媒体平台X上发布消息称,该公司已决定做空“比特币大户”微策略(Microstrategy)这家公司,并认为该公司已经将自己变身成为一家比特币投资基金 ...
- caffycat
- 11 小时前
- 支持
- 反对
- 回复
- 收藏
-
每经AI快讯,11月20日,文远知行宣布旗下自动驾驶环卫车S6与无人扫路机S1分别在新加坡滨海湾海岸大道与滨海艺术中心正式投入运营。据介绍,这是新加坡首个商业化运营的自动驾驶环卫项目。 ...
- star8699
- 前天 19:48
- 支持
- 反对
- 回复
- 收藏
-
上证报中国证券网讯(记者王子霖)11月20日,斗鱼发布2024年第三季度未经审计的财务报告。本季度斗鱼依托丰富的游戏内容生态,充分发挥主播资源和新业务潜力,持续为用户提供高质量的直播内容及游戏服务,进一步 ...
- goodfriendboy
- 前天 20:09
- 支持
- 反对
- 回复
- 收藏
-
人民网北京11月22日电 (记者栗翘楚、任妍)2024广州车展,在新能源汽车占据“半壁江山”的同时,正加速向智能网联新能源汽车全面过渡,随着“端到端”成为新宠,智能驾驶解决方案成为本届广州车展各大车企竞 ...
- 3233340
- 5 小时前
- 支持
- 反对
- 回复
- 收藏